Lucknow: A large interstate network involved in the illegal trade of counterfeit medicines through fraudulent trading practices has come under investigation in Uttar Pradesh. The Food Safety and Drug Administration (FSDA) has uncovered evidence suggesting that fake invoices were being generated without any actual supply of medicines, enabling the illegal movement of suspected counterfeit drugs while portraying the transactions as legitimate. Investigators believe that counterfeit medicines manufactured in Rajasthan, Uttarakhand and Himachal Pradesh were being supplied to markets across Uttar Pradesh and subsequently distributed to other states. Several wholesale drug dealers and pharmaceutical firms have now come under the scanner.
According to FSDA officials, the investigation revealed that certain large pharmaceutical traders allegedly misused the drug licences of small-scale licensed dealers. Instead of supplying genuine medicines, fake purchase and sale invoices were created in the names of these licence holders. These paper transactions were then used to legitimise the movement of counterfeit medicines, while the actual business consisted only of invoice generation and financial adjustments rather than genuine pharmaceutical trade.
Investigators also found evidence of cross-billing among multiple wholesale pharmaceutical firms. Authorities allege that one company issued fraudulent invoices in the name of another, allowing counterfeit medicines to be transported across states under the cover of apparently legitimate documentation. In many instances, investigators believe that no genuine banking transactions accompanied these deals, with only accounting records being created to give the appearance of lawful commercial activity.
The probe further indicates that large operators deliberately targeted licence holders with weak or inactive businesses. Their drug licences were allegedly used to generate invoices in the names of well-known pharmaceutical brands. In return, the small licence holders reportedly received monthly payments of around ₹10,000 to ₹15,000. The same amount was subsequently returned under the guise of medicine purchases, creating a complete paper trail while concealing the true origin and destination of the counterfeit drugs.
Acting on these findings, FSDA teams conducted inspections at 13 pharmaceutical firms located in Aminabad and other areas on Saturday. Based on preliminary evidence and seized records, several firms have been sealed pending further investigation. Officials stated that operations at these establishments will remain suspended until detailed forensic examination of billing records, stock registers, ledgers, purchase and sale documents, and financial transactions is completed. Authorities are also preparing to cancel the drug licences of businesses found guilty of violating pharmaceutical regulations.
Another significant aspect of the investigation involves the FSDA’s ‘Marg’ software platform. Preliminary findings suggest that individuals associated with the counterfeit medicine network may have manipulated certain security features and procedural safeguards within the software to facilitate fraudulent billing. As a result, the department is preparing a wider technical audit of software systems used by pharmaceutical traders across the state to determine whether similar irregularities exist elsewhere.
Public health experts warn that counterfeit medicine trafficking is not merely an economic offence but also a serious threat to public health and patient safety. The use of fake invoices, shell entities and misused drug licences to introduce substandard or counterfeit medicines into the legitimate supply chain can compromise medical treatment, endanger patients’ lives and undermine confidence in the pharmaceutical distribution system. Such practices also result in significant tax losses and unfair competition for legitimate businesses.
FSDA officials said the investigation remains ongoing, with authorities examining digital records, banking transactions, billing data and interstate supply chains to identify the full extent of the network. Investigators are coordinating the verification of commercial records with multiple states to determine whether additional firms and individuals were involved in the alleged racket. Officials have indicated that further searches, licence cancellations and criminal proceedings may follow as more evidence emerges, with the objective of dismantling the interstate counterfeit medicine network and preventing similar fraudulent trading practices in the future.
About the author — Suvedita Nath is a science student with a growing interest in cybercrime and digital safety. She writes on online activity, cyber threats, and technology-driven risks. Her work focuses on clarity, accuracy, and public awareness.
